Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07316088 · ClinicalTrials.gov registry record · Phase 2
Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms
A Phase 2 study of PTSD and Post Traumatic Stress Disorder, sponsored by Oui Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07316088 is a Phase 2 study of PTSD and Post Traumatic Stress Disorder that is actively recruiting participants, run by Oui Therapeutics. The registered enrollment target is 40 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07316088, a Phase 2 study of PTSD and Post Traumatic Stress Disorder, is actively recruiting participants, sponsored by Oui Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is exploring the efficacy of a digital therapeutic app in reducing symptoms of posttraumatic stress disorder (PTSD) in adults.
Conditions Studied
Interventions
- DEVICE OTX-601 Digital Therapeutic
- DEVICE OTX-003 Comparator app
Study Locations (1)
Florida
- Florida State University - Tallahassee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07316088
The ClinicalTrials.gov registry entry for NCT07316088 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (87% lower). The listed sponsor is Oui Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which OTX-601 Digital Therapeutic is the first listed.
NCT07316088 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07316088 about?
NCT07316088 is a clinical study titled "Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms". This study is exploring the efficacy of a digital therapeutic app in reducing symptoms of posttraumatic stress disorder (PTSD) in adults.
What is the current status of trial NCT07316088?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-12-09. Estimated completion is 2026-07-31.
What conditions does trial NCT07316088 study?
This clinical trial studies the following conditions: PTSD, Post Traumatic Stress Disorder.
What interventions are being tested in trial NCT07316088?
The interventions under investigation include: OTX-601 Digital Therapeutic (DEVICE), OTX-003 Comparator app (DEVICE).
Who is sponsoring clinical trial NCT07316088?
This trial is sponsored by Oui Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07316088 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oxytocin to Enhance Integrated Treatment for AUD and PTSD
RECRUITING · Phase 2
-
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
RECRUITING · Phase 2
-
Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Induction of Dreaming With EEG and Anesthesia for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.